Maven Securities LTD Takes Position in Ocular Therapeutix, Inc. $OCUL

Maven Securities LTD bought a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 100,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,169,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Ocular Therapeutix by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 5,156 shares in the last quarter. Caxton Associates LLP acquired a new position in Ocular Therapeutix in the first quarter valued at approximately $248,000. Creative Planning boosted its position in Ocular Therapeutix by 21.5% in the 2nd quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 3,791 shares in the last quarter. Swiss National Bank boosted its position in Ocular Therapeutix by 7.3% in the 2nd quarter. Swiss National Bank now owns 197,400 shares of the biopharmaceutical company’s stock worth $1,832,000 after purchasing an additional 13,400 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Ocular Therapeutix by 110.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company’s stock worth $6,608,000 after purchasing an additional 374,269 shares during the period. 59.21% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Ocular Therapeutix

In related news, Director Richard L. Md Lindstrom acquired 60,229 shares of the firm’s stock in a transaction on Friday, February 20th. The shares were acquired at an average cost of $7.66 per share, with a total value of $461,354.14. Following the completion of the acquisition, the director directly owned 246,933 shares in the company, valued at approximately $1,891,506.78. This trade represents a 32.26% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Pravin Dugel sold 124,882 shares of Ocular Therapeutix stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $1,128,933.28. Following the completion of the sale, the insider owned 3,033,078 shares in the company, valued at approximately $27,419,025.12. This trade represents a 3.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 197,221 shares of company stock valued at $1,754,805. Insiders own 2.30% of the company’s stock.

Ocular Therapeutix Trading Up 0.6%

Shares of OCUL stock opened at $8.68 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -6.03 and a beta of 0.91. The stock has a 50 day simple moving average of $9.72 and a 200-day simple moving average of $11.35. Ocular Therapeutix, Inc. has a 1-year low of $5.80 and a 1-year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $13.25 million for the quarter, compared to analysts’ expectations of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The firm’s revenue for the quarter was down 22.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) EPS. On average, equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on OCUL shares. Needham & Company LLC cut their target price on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating for the company in a report on Friday, February 20th. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a report on Thursday, February 5th. William Blair reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Monday, March 2nd. Finally, HC Wainwright increased their target price on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.78.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.